Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Orphazyme A/S ADR (ORPH)

Orphazyme A/S ADR (ORPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344 Globe Newswire - Mon Aug 8, 2022

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a...

COCP : 2.34 (-0.43%)
ORPH : 0.8700 (-2.25%)
CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C Business Wire - Thu Feb 24, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C Business Wire - Mon Feb 14, 2022

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Comments on Quarterly Results and Recent Strategic Initiatives Business Wire - Fri Nov 12, 2021

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

IBRX : 5.71 (-1.38%)
ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C Business Wire - Tue Nov 2, 2021

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories,...

ORPH : 0.8700 (-2.25%)
CYTR : 0.0920 (unch)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers PR Newswire - Thu Oct 14, 2021

/PRNewswire/ -- USA News Group - Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq...

ONCY : 1.0200 (-0.97%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
Promising New Developments Causing Some Biotech Stocks to Pull Away from Underperforming Peers FinancialNewsMedia - Thu Oct 14, 2021

FN Media Group Presents USA News Group News Commentary   Vancouver, BC –October 14, 2021 – USA News Group  –  Compared to the Dow Jones Industrial Average which has gained an impressive 10.6%...

ONCY : 1.0200 (-0.97%)
ONC.TO : 1.42 (+0.71%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
Biotech Winners Emerging Amid Sector’s Current Bearish Run Baystreet - Thu Oct 14, 2021

Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and ...

ONC.TO : 1.42 (+0.71%)
ORPH : 0.8700 (-2.25%)
JNJ : 154.24 (-0.29%)
SESN : 12.5760 (+7.29%)
CRXT : 0.0475 (-31.16%)
ONCY : 1.0200 (-0.97%)
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses Globe NewsWire - Thu Sep 30, 2021

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter

LSE.LN : 8,620.000 (-0.58%)
AIM : 0.3700 (-0.08%)
ORPH : 0.8700 (-2.25%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orphazyme, CorMedix, Koninklijke Philips, and Sesen Bio and Encourages Investors to Contact the Firm Globe NewsWire - Tue Sep 7, 2021

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders...

ORPH : 0.8700 (-2.25%)
CRMD : 4.74 (+1.94%)
PHG : 26.43 (+2.16%)
SESN : 12.5760 (+7.29%)

Barchart Exclusives

1 Reliable Dividend Stock to Buy at a Discount This July Barchart - Mon Jul 22, 6:30PM CDT
Here’s a dividend-paying gem trading at an attractive valuation, which investors can consider this July while it's still a bargain. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot